BIOMARK ANNOUNCES CHANGE OF AUDITOR
Vancouver, British Columbia – (May 31, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) announces that it has changed its auditors from Manning Elliott LLP (“Former Auditor”) to PricewaterhouseCoopers LLP (“Successor Auditor”). The Former Auditor resigned as the auditor of the Company effective May 17th, 2021 and the board of directors […]
10 Reasons why Biomark BUX is a Buy and Long-term Hold
The article presented on this page may contain forward-looking statements. These statements relate to future events or future financial performance. Any statements that are not statements of historical fact (including without limitation statements to the effect that the Company or its management “believes”, “expects”, “anticipates”, “plans”, and similar statements) should be considered forward looking statements. […]
3 Cancer Diagnostic Stocks To Watch Following Roche’s GenMark Buy
Biotech companies are showing leadership in early detection of cancer. March 16, 2021 Melanie Schaffer , Benzinga Staff Writer In January, Exact Sciences Corporation EXAS 1.59% announced it completed its acquisition of Thrive Earlier Detection Corp. and got Thrive’s blood-based multi-cancer detection technology. Why It Matters: Early detection of cancer greatly increases the survival rate and smaller biotech companies are showing leadership skills in […]
